Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

353
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
353
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

387
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
387
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

351
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
351
Drug Dosage Regimen: Overview01:15

Drug Dosage Regimen: Overview

4.1K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
4.1K
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

377
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
377
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption01:22

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

837
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
837

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Predictive value of BMD for hip and other fractures: a meta-analysis to update FRAX.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026
Same author

Correction: A meta-analysis of previous falls and subsequent fracture risk in cohort studies.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026
Same author

Predictive value of BMD for hip and other fractures: a meta-analysis to update FRAX.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026
Same author

A meta-analysis of smoking and fracture risk to update the FRAX® tool.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026
Same author

Family history of fracture and fracture risk: a meta-analysis to update the FRAX® risk assessment tool.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2025
Same author

Body mass index and subsequent fracture risk: a meta-analysis to update FRAX.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2025

Related Experiment Video

Updated: Apr 21, 2026

Author Spotlight: Fu's Subcutaneous Needling for Knee Osteoarthritis Pain
07:19

Author Spotlight: Fu's Subcutaneous Needling for Knee Osteoarthritis Pain

Published on: March 24, 2023

8.3K

Drug utilization in patients with OA: a population-based study.

Nicholas Wilson1, Lidia Sanchez-Riera1, Rosa Morros1

  • 1Institute of Bone and Joint Research, Kolling Institute of Medical Research, Royal North Shore Hospital, Sydney, NSW, Australia, Global Burden of Diseases Study 2010 Working Group, University of Washington, Seattle, WA, USA, Institut d'Investigació Biomèdica de Bellvitge, Hospital Universitari de Bellvitge, Departament de Reumatologia, L'Hospitalet de Llobregat, Institut Català de la Salut, Primary Care Department, IDIAP Jordi Gol, SIDIAP Database, Institut Català de la Salut, URFOA-IMIM and RETICEF, Internal Medicine, Parc de Salut Mar-Instituto Carlos III, Barcelona, Spain, Musculoskeletal Epidemiology Unit, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford and MRC Lifecourse Epidemiology Unit, Southampton University, Southampton, UK Institute of Bone and Joint Research, Kolling Institute of Medical Research, Royal North Shore Hospital, Sydney, NSW, Australia, Global Burden of Diseases Study 2010 Working Group, University of Washington, Seattle, WA, USA, Institut d'Investigació Biomèdica de Bellvitge, Hospital Universitari de Bellvitge, Departament de Reumatologia, L'Hospitalet de Llobregat, Institut Català de la Salut, Primary Care Department, IDIAP Jordi Gol, SIDIAP Database, Institut Català de la Salut, URFOA-IMIM and RETICEF, Internal Medicine, Parc de Salut Mar-Instituto Carlos III, Barcelona, Spain, Musculoskeletal Epidemiology Unit, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford and MRC Lifecourse Epidemiology Unit, Southampton University, Southampton, UK.

Rheumatology (Oxford, England)
|October 24, 2014
PubMed
Summary

Osteoarthritis (OA) patients commonly use multiple medications, increasing risks of drug interactions. The use of opioids and COX-2 inhibitors for OA is rising, raising safety and cost concerns.

Keywords:
Cataloniadrug utilizationelectronic health recordsosteoarthritispharmaceutical therapypharmacoepidemiologypopulation-based cohort

More Related Videos

Tissue Collection and RNA Extraction from the Human Osteoarthritic Knee Joint
06:06

Tissue Collection and RNA Extraction from the Human Osteoarthritic Knee Joint

Published on: July 22, 2021

6.0K
Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

1.2K

Related Experiment Videos

Last Updated: Apr 21, 2026

Author Spotlight: Fu's Subcutaneous Needling for Knee Osteoarthritis Pain
07:19

Author Spotlight: Fu's Subcutaneous Needling for Knee Osteoarthritis Pain

Published on: March 24, 2023

8.3K
Tissue Collection and RNA Extraction from the Human Osteoarthritic Knee Joint
06:06

Tissue Collection and RNA Extraction from the Human Osteoarthritic Knee Joint

Published on: July 22, 2021

6.0K
Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

1.2K

Area of Science:

  • Rheumatology
  • Pharmacology
  • Public Health

Background:

  • Osteoarthritis (OA) management involves diverse drug therapies.
  • Understanding medication use patterns and combinations is crucial for patient safety.

Purpose of the Study:

  • To investigate the prevalence and combinations of OA medications in a large population-based cohort in Catalonia, Spain.
  • To characterize users of different OA drugs, focusing on cardiovascular risk factors.
  • To analyze trends in drug utilization over a five-year period.

Main Methods:

  • Utilized the SIDIAP database, encompassing electronic medical records and pharmacy data for over 5 million individuals.
  • Included patients with an OA diagnosis between 2006-2010.
  • Analyzed utilization of NSAIDs, analgesics, opioids, COX-2 inhibitors, and slow-acting OA drugs using medication possession ratios (MPRs).

Main Results:

  • Identified 238,536 OA patients.
  • Over half (53.9%) used at least three different drugs concurrently.
  • Chondroitin, glucosamine, and oral NSAIDs were the most frequently used regular medications.
  • Opioid, COX-2 inhibitor, and chondroitin use increased, while other drug use declined.

Conclusions:

  • Polypharmacy is prevalent in OA treatment, posing risks of drug interactions.
  • The increasing incidence of opioid and COX-2 inhibitor use warrants attention due to safety and cost implications.